New EU regulations aim to speed up health technology assessments (HTAs), but the pharma industry raises logistical concerns.

Anavex Life Sciences Corp.'s stock rises 50% as EMA reviews Alzheimer's drug blarcamesine. Click for my updated look at AVXL stock and why I have upgraded it.

Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

Q4 2024 Management View CEO Mihael Polymeropoulos highlighted strong revenue growth for Fanapt, driven by its launch for bipolar I disorder and increased new-to-brand prescriptions by over 160% ...

Enzeevu (aflibercept-abzv), a biosimilar developed by Sandoz, demonstrated biosimilarity to reference aflibercept (Eylea) in ...

There exists no ‘amyloid cabal’” in Alzheimer’s research, neurologist Dennis Selkoe writes in response to Charles Piller’s “Doctored.” ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

The FDA has approved Evrysdi in tablet form for patients with spinal muscular atrophy aged 2 years and older who weigh more ...

The European Space Research and Technology Centre (ESTEC) is the European Space Agency's main technology development and test centre for spacecraft and space technology. It is situated in Noordwijk, ...